OBLN Obalon Therapeutics

DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Obalon Therapeutics, Inc. to Contact the Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Obalon Therapeutics, Inc. (Nasdaq: OBLN) (“Obalon” or the “Company”) securities during the period between October 5, 2016 and January 23, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Obalon securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company recognized revenue in violation of Generally Accepted Accounting principles and that the Company lacked adequate internal controls over accounting and financial reporting.

According to the complaint, following Obalon’s January 23, 2018 a press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017” and that “Obalon’s Audit Committee will oversee an internal investigation of these allegations,” the value of Obalon shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Obalon securities purchased on or after October 5, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
16/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obalon Therapeutics

 PRESS RELEASE

Obalon Announces First Quarter 2021 Financial Results

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...

 PRESS RELEASE

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...

 PRESS RELEASE

Obalon Announces Third Quarter 2020 Financial Results

Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...

 PRESS RELEASE

Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...

 PRESS RELEASE

Obalon Announces Second Quarter 2020 Financial Results

Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch